Seres Therapeutics, Inc. (MCRB), a company specializing in live biotherapeutics, announced on Thursday that it has received a $50 million installment payment from the sale of its VOWST division to Nestlé Health Science. This payment was made to fulfill the company's transitional responsibilities.
Additionally, Seres Therapeutics indicated that, as previously disclosed, the company's cash reserves and cash equivalents—which include this recent $50 million payment and an anticipated $25 million installment due in July—are projected to support their operational expenses through the first quarter of 2026.
